Frequency and percentage of cytogenetic abnormalities in Medical Research Council trial AML11
| Abnormality . | All patients (n = 1065), no. (%) . | Age group, y . | Median age, y . | Median initial WBC* . | Type of AML . | |||
|---|---|---|---|---|---|---|---|---|
| Younger than 65 (n = 440), % . | 65-69 (n = 334), % . | 70 and older (n = 291), % . | de novo (n = 817), % . | Secondary (n = 248), % . | ||||
| Overall | 66 | 10.9 | ||||||
| No abnormality | 507 (48) | 45 | 47 | 52 | 66 | 19.8 | 50 | 39 |
| Complex | 146 (14) | 12 | 19 | 11 | 66 | 4.3† | 12 | 18‡ |
| +8 | 109 (10) | 10 | 10 | 11 | 67 | 6.4† | 9 | 15† |
| −7 | 87 (8) | 8 | 9 | 7 | 66 | 4.7† | 7 | 13† |
| del(5q) | 80 (8) | 7 | 10 | 5 | 66 | 4.3† | 7 | 10 |
| −5 | 55 (5) | 4 | 7 | 4 | 66 | 2.8† | 5 | 7 |
| del(7q) | 48 (5) | 6 | 3 | 3‡ | 64 | 5.2‡ | 4 | 5 |
| t(15;17) | 43 (4) | 6 | 4 | 2‡ | 63† | 1.7† | 5 | 1 |
| abn(3q) | 27 (3) | 2 | 4 | 2 | 66 | 7.0 | 2 | 4 |
| +21 | 26 (2) | 2 | 3 | 3 | 67 | 7.8 | 2 | 3 |
| del(9q) | 24 (2) | 3 | 2 | 1 | 64 | 10.1 | 2 | 2 |
| t(8;21) | 23 (2) | 3 | 2 | 2 | 65 | 13.0 | 2 | 2 |
| +22 | 15 (1) | 2 | 2 | 1 | 65 | 3.3‡ | 1 | 2 |
| inv(16) | 12 (1) | 1 | 1 | 1 | 65 | 11.3 | 2 | 0 |
| 11q23 | 11 (1) | 1 | 1 | 1 | 64 | 9.0 | 1 | 2 |
| Other numerical | 277 (26) | 25 | 28 | 25 | 66 | 5.5† | 25 | 29 |
| Other structural | 295 (28) | 28 | 31 | 23 | 66 | 5.4† | 25 | 38† |
| Abnormality . | All patients (n = 1065), no. (%) . | Age group, y . | Median age, y . | Median initial WBC* . | Type of AML . | |||
|---|---|---|---|---|---|---|---|---|
| Younger than 65 (n = 440), % . | 65-69 (n = 334), % . | 70 and older (n = 291), % . | de novo (n = 817), % . | Secondary (n = 248), % . | ||||
| Overall | 66 | 10.9 | ||||||
| No abnormality | 507 (48) | 45 | 47 | 52 | 66 | 19.8 | 50 | 39 |
| Complex | 146 (14) | 12 | 19 | 11 | 66 | 4.3† | 12 | 18‡ |
| +8 | 109 (10) | 10 | 10 | 11 | 67 | 6.4† | 9 | 15† |
| −7 | 87 (8) | 8 | 9 | 7 | 66 | 4.7† | 7 | 13† |
| del(5q) | 80 (8) | 7 | 10 | 5 | 66 | 4.3† | 7 | 10 |
| −5 | 55 (5) | 4 | 7 | 4 | 66 | 2.8† | 5 | 7 |
| del(7q) | 48 (5) | 6 | 3 | 3‡ | 64 | 5.2‡ | 4 | 5 |
| t(15;17) | 43 (4) | 6 | 4 | 2‡ | 63† | 1.7† | 5 | 1 |
| abn(3q) | 27 (3) | 2 | 4 | 2 | 66 | 7.0 | 2 | 4 |
| +21 | 26 (2) | 2 | 3 | 3 | 67 | 7.8 | 2 | 3 |
| del(9q) | 24 (2) | 3 | 2 | 1 | 64 | 10.1 | 2 | 2 |
| t(8;21) | 23 (2) | 3 | 2 | 2 | 65 | 13.0 | 2 | 2 |
| +22 | 15 (1) | 2 | 2 | 1 | 65 | 3.3‡ | 1 | 2 |
| inv(16) | 12 (1) | 1 | 1 | 1 | 65 | 11.3 | 2 | 0 |
| 11q23 | 11 (1) | 1 | 1 | 1 | 64 | 9.0 | 1 | 2 |
| Other numerical | 277 (26) | 25 | 28 | 25 | 66 | 5.5† | 25 | 29 |
| Other structural | 295 (28) | 28 | 31 | 23 | 66 | 5.4† | 25 | 38† |
Percentages indicate percentage of column total. Percentages do not add to 100 because patients with more than one abnormality are counted more than once. P values are for Mantel-Haenszel test for trend in age (grouped), for Wilcoxon 2-sample test in age and initial WBC (continuous), and for Fisher exact test in type of AML, comparing each abnormality with normal karyotype (ie, no abnormality).
WBC indicates white blood count; AML, acute myeloid leukemia; abn, abnormal.
Initial WBC was not recorded for 22 patients.
P < .001.
P < .01.